Baird Medical Investment Holdings Limited

What they do

The company develops and sells microwave ablation medical devices for treating thyroid nodules and breast lumps in China, distributing through direct sales, deliverers, and distributors. Its product pipeline includes AI-integrated robotic ablation systems, with R&D partnerships with Nanjing Forestry University and Zhuhai People's Hospital. The company also claims to rank first among microwave ablation needle providers in China by sales revenue and volume for thyroid and breast treatments in 2022.

Revenue drivers

• Microwave ablation systems and needles — Core products for thyroid and breast treatment; sales revenue was $35.1M (2022), $31.5M (2023), $37.0M (2024), and $22.5M (2025).
• Direct sales, deliverers, and distributors — Products are sold via these three channels; distributor network cut costs and time to reach target markets, with number of purchasing hospitals rising from ~505 (2023) to ~579 (2024) and 614 (2025).
• Geographic focus on China — All reported revenue is from China; the company's market position in microwave ablation for thyroid and breast lumps underpins its revenue base.

Recent performance

Revenue fell from $37.0M in 2024 to $22.5M in 2025, a decline of ~39%, while net income swung from a $12.5M profit to a $-27.3M loss. Diluted EPS dropped from $0.57 to $-0.98. Operating cash flow was negative for the third consecutive year at $-1.3M (2025). The company ended 2025 with cash and equivalents of just $178,321 against total assets of $69.7M and long-term debt of $6.1M.

Strategy

Management aims to become the first global platform company dedicated to precision thyroid health, building an ecosystem from screening and diagnosis to robotic-assisted ablation and post-treatment care. The strategy includes expanding the product pipeline beyond microwave ablation to AI-integrated robotic systems and leveraging distributor networks to grow hospital coverage. R&D partnerships with academic and hospital institutions underpin the development of new devices. The focus is on intelligent, non-invasive thyroid treatments in a highly specialized market.

Risks

• Cash depletion — Cash of $178K at end-2025 is extremely low relative to negative operating cash flow and total liabilities of $38.5M, raising going-concern concerns.
• Revenue decline — 2025 revenue fell 39% year-over-year, and net income turned into a large loss.
• Business interruption from restatement — The 20-F/A was filed to amend the original 20-F due to SEC comments, indicating potential accounting or disclosure issues that may affect investor confidence.
• China concentration — All operations and revenue are in China, exposing the company to regulatory, economic, and geopolitical risks in that market.

Outlook

Management does not provide specific forward guidance in the provided excerpts, but the company continues to invest in R&D for AI-integrated robotic systems and aims to expand its hospital network. The outlook is challenged by the 2025 revenue decline and liquidity constraints, but growth may come from new product pipeline and market expansion in thyroid care.